STEVE LIZANO: Open Payments
NPI 1972107878 · OAKLAND PARK, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,773 in 173 payments from 21 companies in 2025. Trend: 2023 $4,790 · 2024 $7,571 · 2025 $3,773
Food & beverage: $3,761Education: $12
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 37 | $915 |
| ViiV Healthcare Company | 39 | $812 |
| Theratechnologies Inc. | 8 | $300 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $259 |
| Novo Nordisk Inc | 14 | $257 |
| Axsome Therapeutics, Inc. | 6 | $191 |
| Merck Sharp & Dohme LLC | 7 | $166 |
| Amgen Inc. | 20 | $155 |
| Lilly USA, LLC | 5 | $153 |
| AstraZeneca Pharmaceuticals LP | 3 | $150 |
Products named: DOVATO, EGRIFTA, APRETUDE, CAPLYTA, Auvelity, PIFELTRO, CABENUVA, ZEPBOUND.
Industry payments across FL — which companies pay providers there.
